# Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

> **NCT05983276** · PHASE2 · RECRUITING · sponsor: **Loyola University** · enrollment: 40 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT05983276
- **Lead sponsor:** Loyola University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-16
- **Primary completion:** 2030-08-28
- **Final completion:** 2031-08-28
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05983276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05983276, "Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05983276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*